S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
Log in

15 Healthcare Stocks that Analysts Love in 2020

Posted on Monday, January 20th, 2020 by MarketBeat Staff

There are more than 200 healthcare companies traded on public markets. Given the sheer number of pharmaceutical companies, medical research firms, hospital systems and other healthcare stocks, it can be hard to identify which healthcare companies are going to outperform the market.

Fortunately, Wall Street's brightest minds have already done this for us. Every year, analyst issue approximately 3,000 distinct recommendations for healthcare companies. Analysts don't always get their "buy" ratings right, but it's worth taking a hard look when several analysts from different brokerages and research firm are giving "strong buy" and "buy" ratings to the same healthcare stock.

This slide show lists the 15 healthcare companies that have the highest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.

#1 - AzurRx BioPharma (NASDAQ:AZRX)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $7.10 (512.1% Upside)

AzurRx BioPharma logoAzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea. The company was incorporated in 2014 and is headquartered in Brooklyn, New York.

#2 - Knight Therapeutics (TSE:GUD)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: C$9.58 (19.5% Upside)

Knight Therapeutics logoKnight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea. The company also develops Probuphine to treat opioid addiction; NeurAxon family for acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; AzaSite for bacterial conjunctivitis; Iluvien to treat diabetic macular edema; Netildex for ocular inflammation; 60P family to treat tropical diseases; Advaxis family to treat HPV-associated cancers and others; PHOTOFRIN for oesophageal and endobronchial cancer, high-grade dysplasia in Barrett's oesophagus, and papillary bladder cancer; ATryn to prevent thromboembolic events; Ember family to treat osteoarthritis, chronic kidney diseases, alport syndrome, and metabolic diseases; and blood factor products. In addition, it develops FLEXISEQ for pain and joint stiffness associated with osteoarthritis; dermo-cosmetic line of products, such as Crescita family, Laboratoire Dr. Renaud, Premiology, and Pro-Derm; SEQuaderma, an active dermatology solution; HandMD skin care products; and UrgentRx, a fast-acting, portable over-the-counter medication. Further, the company develops TULSA-PRO, a medical device for prostate ablation; and 3D family diagnostic and prognostic products for cancers and neurological disorders. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company is headquartered in Montreal, Canada.

#3 - Medical Transcription Billing (NASDAQ:MTBC)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $6.08 (28.6% Upside)

Medical Transcription Billing logoMedical Transcription Billing, Corp. is a healthcare information technology company that provides an integrated suite of Web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. The Company's offering, PracticePro, allows healthcare practices with the core software and business services on Software-as-a-Service (SaaS) platform. PracticePro includes practice management software and related tools, which facilitate the day-to-day operation of a medical practice; electronic health records (EHR), which allow its customers to qualify for government incentives; revenue cycle management (RCM) services, which include medical billing, analytics and related services, and mobile Health (mHealth) solutions, including smartphone applications that assist patients and healthcare providers in the provision of healthcare services. The Company offers a clearinghouse service, which allows clients to track claim status.

#4 - Progyny (NASDAQ:PGNY)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $29.67 (-2.7% Upside)

Progyny logoProgyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption expenses for clients and their employees. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

#5 - InMode (NASDAQ:INMD)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $37.00 (-17.9% Upside)

InMode logoInMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. InMode Ltd. offers its products directly in the United States, Canada, the United Kingdom, Spain, and India, as well as indirectly through third-party distributors internationally. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.

#6 - Green Thumb Industries (OTCMKTS:GTBIF)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $17.50 (69.4% Upside)

Green Thumb Industries logoGreen Thumb Industries Inc. manufactures and sells various cannabis products in the United States. The company's cannabis products include flower, concentrates for dabbing and vaporizing, edibles, and topical. It owns and operates a chain of retail cannabis stores under the RISE name. The company markets its products through third party retailers. As of January 28, 2019, it licensed for 70 retail locations across 9 regulated U.S. markets. The company was founded in 2014 and is headquartered in Chicago, Illinois.

#7 - Exicure (OTCMKTS:XCUR)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $7.33 (194.5% Upside)

Exicure logoExicure, Inc. engages in the provision of clinical stage biotechnology company. It offers 3-dimensional, spherical nucleic acid architecture unlocks the potential of nucleic acid therapeutics. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.

#8 - SpringWorks Therapeutics (NASDAQ:SWTX)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $34.00 (-4.1% Upside)

SpringWorks Therapeutics logoSpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its advanced product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; and Nirogacestat + belantamab mafodotin, which is in Phase 1b clinical trials for the treatment of relapsed or refractory multiple myeloma. In addition, it is developing Mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trials in patients with advanced or refractory solid tumors; and BGB-3245, an investigational oral selective small molecule inhibitor of specific BRAF driver mutations and genetic fusions, which is in preclinical studies in a range of tumor models with BRAF mutations or fusions. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline plc to develop combination approaches with nirogacestat and mirdametinib, as well as other standalone medicines. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

#9 - So-Young International (NASDAQ:SY)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $18.65 (26.3% Upside)

So-Young International logoSo-Young International Inc. operates an online platform for discovering, evaluating, and reserving medical aesthetic services. The company facilitates research for treatments, read reviews about them, and book appointments on the platform and blog under the name Beauty Diaries. Its platform enables users to discover content and share their own experience on medical aesthetics procedures, and leads users to reserve treatment services from medical aesthetic service providers for offline treatment in China and internationally. The company provides Software as a Service and professional training programs for medical service providers in aesthetic, dental, dermatology, ophthalmology, gynecology, and physical examination sectors. So-Young International Inc. was founded in 2013 and is headquartered in Beijing, China.

#10 - IMV (TSE:IMV)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: C$9.75 (87.5% Upside)

IMV logoIMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DPX drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. The company develops DPX-Survivac, T cell activating immunotherapy that is in Phase II clinical trials for ovarian cancer and diffuse large B-cell lymphoma. It also develops DPX-RSV, a B cell epitope peptide vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7; and vaccine candidates for malaria and the Zika virus. The company has collaboration and license agreement with Merck & Co., Inc., Dana-Farber Cancer Institute, Incyte Corporation, and Leidos Inc, as well as with Zoetis. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

#11 - TELA Bio (NASDAQ:TELA)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $19.60 (31.3% Upside)

TELA Bio logoTELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. It offers reinforced tissue matrix products for a variety of reconstruction procedures, including hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. The company provides a portfolio of OviTex Reinforced Tissue Matrix or OviTex products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix or OviTex PRS products to address the unmet needs in plastic and reconstructive surgery. It markets its products through a single direct sales force, principally in the United States. The company was founded in 2012 and is headquartered in Malvern, Pennsylvania.

#12 - AdaptHealth (NASDAQ:AHCO)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $13.25 (15.1% Upside)

AdaptHealth logoAdaptHealth, LLC distributes home medical equipment. The Company offers mobility products, respiratory therapy, non- invasive ventilation, nutrition supplies, ocean home health products, sleep therapy supplies, bed lifts, seat lift chairs, and bath aids. AdaptHealth, LLC was founded in 2012 and is based in Phoenixville, Pennsylvania.

#13 - Cresco Labs (OTCMKTS:CRLBF)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $12.33 (84.4% Upside)

Cresco Labs logoCresco Labs Inc. cultivates, manufactures, and sells medical cannabis and medical cannabis products in the United States. It offers cannabis in flower, vape pens, and various forms of extracts under the cresco and Reserve brands; precisely-dosed and non-combustible products, including tinctures, capsules, salves, sublingual oils, and transdermal patches under the Remedi brand; culinary-backed and cannabis-infused edibles under the Mindy's Artisanal brand; and fruity confections under the Mindy's Kitchen brand. As of June 12, 2019, it operated 20 dispensaries in Florida. The company is headquartered in Chicago, Illinois.

#14 - BioCardia (OTCMKTS:BCDA)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $18.33 (256.7% Upside)

BioCardia logoBioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system; and Morph vascular access product line, which provides catheter products. BioCardia, Inc. is based in San Carlos, California.

#15 - Centogene (NASDAQ:CNTG)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $16.67 (22.0% Upside)

Centogene logoCentogene B.V. operates as a commercial-stage rare disease company worldwide. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It operates through two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Diagnostics segment provides genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene B.V. was founded in 2006 and is headquartered in Rostock, Germany.





More on MarketBeat
8 Retail Stocks to Own For the Long Haul8 Retail Stocks to Own For the Long Haul
20 "Past Their Prime" Stocks to Dump From Your Portfolio20 "Past Their Prime" Stocks to Dump From Your Portfolio
15 Technology Stocks that Analysts Love15 Technology Stocks that Analysts Love
20 Stocks Analysts Can20 Stocks Analysts Can't Stop Upgrading
Best Growth Stocks - Best Stocks to Buy NowBest Growth Stocks - Best Stocks to Buy Now
15 Energy Stocks Analysts Love the Most15 Energy Stocks Analysts Love the Most
7 Best Stocks to Own Right Now7 Best Stocks to Own Right Now



Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel